Pfizer Forecasts Flat Growth in 2026 Amid Pipeline Refresh
Pfizer projects $59.5-62.5B revenue for 2026 with minimal growth as it invests in obesity drugs and cuts costs while COVID sales decline and key patents expire.
NOTRELOAD AI
Craig-Hallum Initiates Buy on Jumia with $18 Target
Craig-Hallum starts coverage of Jumia with a Buy rating, highlighting growth potential in African e-commerce and long-term upside of $125-$250 per share.
Nektar's Alopecia Drug Shows Promise But Raises Concerns
Nektar's (NKTR) rezpegaldesleukin demonstrates hair regrowth in alopecia areata patients but narrowly misses primary endpoint, presenting mixed results as company advances to Phase 3 trials.
Adagene's Cancer Treatment Gets FDA Fast Track Status
Adagene receives FDA Fast Track designation for muzastotug, a novel cancer therapy targeting hard-to-treat colorectal cancer patients.
BofA Boosts Estee Lauder Price Target to $130, Names It a Top Beauty Pick
BofA raises Estee Lauder price target to $130 and adds it to its top “US 1 list,” citing strong growth potential and the Beauty Reimagined plan.
Wells Fargo Updates Ratings on Capri, Gap, and Victoria’s Secret
Wells Fargo adjusts ratings and price targets for Capri, Gap, and Victoria’s Secret, highlighting sector trends and optimism for 2026.